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Percutaneous vertebral augmentation are all minimally invasive 
procedures aimed to obtain pain relief,  vertebral consolidation and height 
restoration in symptomatic vertebral fractures and lesions. All of these 
procedures are performed under radiologic guidance (usually fluoroscopy and 
Computed Tomography) gaining percutaneous access to vertebral bodies 
through needles and cannulas. The meaning of vertebral augmentation should 
imply the aim of increasing vertebral height, therefore is commonly intended 
for procedures specifically designed for that purpose such as kyphoplasty and 
vertebral endoprosthesis placement. Nevertheless vertebroplasty is also able to 
provide vertebral height restoration in unstable fractures and Kummel’s disease 
or when performed with thicker cements. 
Vertebroplasty is furthermore included in a consensus statement on 
percutaneus vertebral augmentation recently developed by the American 
Society of Interventional and Therapeutic Neuroradiology, Society of 
Interventional Radiology, American Association of Neurological 
Surgeons/Congress of Neurological Surgeons, and American Society of Spine 
Radiology1. 
The first vertebral augmentation procedure can thus be considered the 
vertebroplasty performed in 1984 by Hervè Deramond, a French interventional 
radiologist, treating an aggressive angioma of the second cervical vertebra2. In 
1991 vertebroplasty was then performed to treat osteoporotic fractures3 and 
later on for the sympthomatic treatment of spinal metastases and vertebral 
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fractures due to multiple myeloma 4-6; vertebroplasty found further applications 
for rarer painful vertebral lesions such as the ones related to Langherans 
disease7 and osteogenesis imperfecta8 . 
In 1998 Mark Reiley, an American orthopedic surgeon, conceived and patented 
a bone tamp designed to be inflated inside the collapsed vertebra in order to lift 
the endplates before cement injection aiming to achieve height restoration and 
kyphosis reduction in addition to pain relief 9,10 
More recently some permanent endoprostheses have been designed to be 
percutaneously introduced inside collapsed vertebral bodies and then encased 
in bone cement. “Prosthesis –assisted” kyphoplasty should avoid vertebral 
elastic recoil following balloon/device deflation and withdrawal because 
expanded permanent prostheses are able to maintain the gained vertebral height 
during bone cement injection. 
 
- Indications and contraindications   
 
Vertebral augmentation can be considered as part of pain management and thus 
the common indication of the different percutaneous spine interventions shoud 
be “back pain” clinically amenable to a pathologic vertebral condition (fracture 
or lesion) found with radiological imaging. All vertebral augmentation 
procedures can provide pain relief but any of them have different features and 
should be tailored to each case. 
As vertebroplasty is the oldest among vertebral augmentation procedures is 
also the one that gained the widest consensus on its application. 
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In 2009 an official practice guideline on vertebroplasty was created 
collaboratively by the American College of Radiology (ACR), the American 
Society of Neuroradiology (ASNR), the Society of Neurointerventional 
Surgery (SNIS), the American Society of Spine Radiology (ASSR), and the 
Society of Interventional Radiology (SIR)11. Indications and contraindications 
of percutaneous vertebroplasty were stated as follows: 
Indications: 
  
1. Painful osteoporotic or neoplastic vertebral compression fracture(s) refractory 
to medical therapy.  
 
2. Symptomatic vertebral body microfracture (as documented by magnetic 
resonance imaging [MRI] or nuclear imaging, and/or lytic lesion seen on CT) 
without obvious loss of vertebral body height.  
 
 
Gudelines published by Society of Interventional Radiology (SIR) in 200312 
were more specific about the kind of fracture to be treated with vertebroplasty. 
 
1.Painful primary and secondary osteoporotic vertebral compression  
fracture(s) refractory to medical therapy.  
 
2. Painful vertebrae with extensive osteolysis or invasion secondary to  
benign or malignant tumor (ie, hemangioma, multiple myeloma, or  
metastatic disease).  
 
3. Painful vertebral fracture associated with osteonecrosis (Kummell  
Disease).  
 
SIR guidelines stress the precise indication of vertebroplasty in vertebral 
osteonecrosis, also called Kummell’s disease, that is an unhealed and mobile 
cronic fracture with gas and/or fluid collections within vertebral body. This 
painful pathologic condition, often misdiagnosed, is maybe the one that benefit 
most from vertebroplasty (as bone cement stops vertebral fracture motion) and 
less from conservative treatment (as osteonecrotic bone has a slow and difficult 
healing). 
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With the Consensus Statement on vertebral augmentation developed in 20071, 
on the basis of available literature review, was determined that the clinical 
outcome in patients treated with kyphoplasty is comparable to that seen in 
patients treated with vertebroplasty. In the absence of a proven advantage of 
one procedure over the other regarding pain relief, vertebral height restoration, 
or complication rate both vertebral augmentation procedures are considered 
established, safe and effective treatment for painful compression fractures. 
No official guidelines have currently defined different indications and 
contraindications for vertebroplasty and kyphoplasty. 
The previously cited guidelines from ACR 11 stated what follows regarding 




1. Asymptomatic vertebral body compression fractures.  
2. Active osteomyelitis of the target vertebra.  
3. Uncorrectable coagulopathy.  
4. Allergy to bone cement or opacification agent. 
5. Patient improving on medical therapy.  
6. Prophylaxis in osteoporotic patients (unless being performed as part of a 
research protocol).  
7. Myelopathy originating at the fracture level.  
 
 
Relative Contraindications  
 
1. Radiculopathy in excess of local vertebral pain, caused by a compressive 
syndrome unrelated to vertebral collapse. Occasionally preoperative 
vertebroplasty can be performed before a spinal decompressive procedure.  
2. Retropulsion of a fracture fragment causing severe spinal canal compromise.  
3. Epidural tumor extension with significant encroachment on the spinal canal.  
4. Ongoing systemic infection.  
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Severe vertebral collapses, also called “vertebra plana”, were considered in the 
past as a relative contraindication for vertebroplasty13. The treatment of such 
fractures has already been reported in the past14,15 with good outcomes and are 
no longer an issue for skilled physicians with adequate angiographic equipment 
and are not listed among contraindications in official guidelines anymore. 
Relative contraindications of vertebral augmentation other than those cited in 
official guidelines depend upon operator’s skills and the ability of the patient to 
lie in the prone position long enough during intervention 16. 
 
- Clinical examination 
 
Clinical examination and interview with the patient undergoing vertebral 
augmentation are fondamental in the pre-procedural assessment.  
Vertebral augmentation procedures are intended for pain management and thus 
imaging findings must match with clinical symptoms. Back pain is a common  
symptom as much as vertebral deformities are frequent radiological findings 
thus we must exclude different painful causes to avoid “image treatment” 
instead of pain treatment. 
Pain at palpation over spinous processes corresponding to the fractured 
level represents an important clinical feature in order to match image and 
symptoms expecially in patients with multiple fractures with different “ages” 
or with multiple metastases. The presence or absence of the so called 
“tenderness point” shouldn’t be a mandatory feature: a paper by Gaughen et al. 
showed that the lack of this sign didn’t affect clinical outcome17.  
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Additional information regarding pain features can be obtained by 
clinical interview as each fracture or lesion has different pain onset depending 
on the anatomic site. Usually when the mid-thoracic spine is involved the 
patient perceives pain between the scapulas during coughing, breathing, 
sneezing or during trunk torsion. When the thoraco-lumbar region is affected 
the patient feels pain during trunk flexions or while getting up from the bed 
(tipically patients can’t raise themselves into a sitting position). When the 
lumbar region is affected pain is exacerbated from a prolonged sitting or 
standing position depending if the mid-lumbar or lumbo-sacral vertebrae are 
involved. As for any pain procedure, perceived pain, quality of life and pain 
medication must be quantified at baseline in order to assess the clinical 
outcome of the procedures.  
There are plenty of questionnaires, indexes and scores available that can be 
used to evaluate pain, mobility and quality of life before treatment and during 
follow up. In a review from Davidson et al. 18 24 different questionnaires on 
quality of life and “back pain” assessments were found on Medline; among 
these only five met authors’ criteria in terms of clinical relevance, reliability 
and simplicity (considering the old mean age of the treated population): 
modified Oswestry Disability Questionnaire, Quebec Back Pain Disability 
Scale, Roland-Morris Disability Questionnaire, Waddell Disability Index, and 
36-Item Short-Form Health Survey (SF-36). Most of these questionnaires are 
very complete because they assess global quality of life including pain, 
mobility, physical and psychic wellness but, on the other hand, their length and 
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complexity represent a limitation considering the older age of the target 
population. Visual Analogue Scale (VAS score) first introduced from Huskisson 
in 1979 19, is a basic and intuitive method where the patient is asked to indicate 
his pain on a given number on a 10 cm ruler (considering 0 as no pain at all and 
10 as the worst pain ever felt in life). More often it is simply used to ask the 
patients to rate their perceived pain “from 0 to 10” and it can easily be asked in 
phone interviews during follow up. Ease of use of  the VAS make this 
assessment appliable to patients of any age, mental status and culture; even if it 
is less complete of other questionnaires a VAS drop in score leads to a quality 
of life improvement.  
 
- Imaging 
Diagnostic imaging has a key role in patient’s selection together with clinical 
evaluation. Often patients with back pain come to observation with plain 
radiographs showing a wedge fracture. These patients have to be further 
investigated with magnetic resonance imaging (MRI) as it’s the only imaging 
technique able to evaluate musculoskeletal and neurological structures with the 
highest contrast resolution on bone, cord, nerves and disks. 
Many authors demand MRI as pre-operative evaluation 20 because is able to 
identify benign and malignant lesions before these are visibile on CT and, with 
fat-suppressed sequences, are able to evaluate “age” and “healing” of a 
fracture.  
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Mathis et al. in a review of 200120 found that hyperintensity in fat 
suppressed sequences Short Tau Inversion Recovery (STIR), as sign of bone 
marrow edema and therefore of recent fracture, was a useful tool for the 
selection of vertebral levels to be treated. More recently Tanigawa et al. 
perspectively treated 80 osteoporotic patients presenting with high, mild or 
absent hyperintensity on fractured vertebrae with percutaneous vertebroplasty 
and found that the presence of bone marrow edema is significantly predictive 
of a good clinical outcome of the procedure21. 
Bone scintigraphy should not be considered as a pre-procedural routine 
imaging due to its lack of anatomical information but can be useful in cases of 
multiple fractures where increased drug uptake can highlight higher 
metabolism therefore finding the source of pain 22.  Kallmes et al. 23 described a 
case with many collapsed vertebrae and no hyperintensity on fat-suppressed 
MRI sequences where the single level showing uptake was treated with 
vertebroplasty obtaining pain relief.  
Computer tomography (CT) can take place of MRI when the latter is 
contraindicated (claustrophobia, presence of pace-makers or prostheses) or can 
be integrated with other imaging modalities taking advantage of its higher 
spacial resolution on bone matrix and cortex. CT scan, readily available and 
commonly performed in oncologic patients during follow up, can be aquired 
with a thin slice protocol and post-processed with multiplanar reconstructions 
obtaining a precise depiction of fractures and clefts in the bone. Furthermore 
CT scan can clearly determine whether a metastatic lesion is osteolythic, 
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depicting gaps of cortical bone where bone cement can leak, or osteoblastic 
where vertebral augmentation is usually contraindicated.   
If we need to find an “ideal” second level pre-procedural imaging modality for 
vertebral augmentation we should finally choose MRI because it’s the one that 
merges the higher anatomical information on a wider spectrum of spinal 
structures with a good functional information provided by signal features in 
basal sequences (calcium, blood, air, water, edema), spectroscopy (metabolites) 
and contrast administration (vascularization). 
 
- Fracture Age 
In osteoporotic patients vertebroplasty is usually performed after 4-6 
weeks of conservative treatment without evidence of clinical benefit 24-28.  This 
is justifiable because more than 50% of patients eligible for vertebroplasty can 
have fracture healing and pain relief just with brace support, bed rest and pain 
medication alone29. Fracture age shouldn’t affect vertebroplasty outcome as 
found by Kauffman et al 30 with the exception of older patients with chronic 
usage of analgesics possibly due to the dependency. Brown et al. found in a 
retrospective study no statistically significant difference in pain relief obtained 
after vertebroplasty in patients treated for sub-acute fractures or cronic 
fractures less than 12 months while clinical outcome in terms of pain relief was 
worse for patients with vertebral fractures older than 24 months 31.  
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- Vertebroplasty and Kyphoplasty 
Based on vertebroplasty experience kyphoplasty was introduced in the late 
nineties 9,32. Kyphoplasty is performed with the intent of restoring vertebral 
height and correct kyphosis in traumatic or osteoporotic fractures less than 3 
month old but it adds higher costs and risks to vertebroplasty without evidence 
of a better outcome 33. Indications, contraindications and effectiveness of the 
procedure have been debated for a long time and a recent literature meta-
analysis concluded that both vertebral augmentation procedures are comparable 
in terms of clinical outcome and new vertebral fracture rate 34. Nevertheless 
meta-analyses are affected by intrinsic limits with these kinds of studies and 
further investigations like large randomized controlled trials on vertebroplasty 
versus other vertebral augmentation procedures are warranted.  
 
- Mechanisms of pain relief 
The underlying mechanisms postulated for pain relief provided by bone cement 
injected during spine interventions are mainly three: chemotoxicity of methyl 
methacrylate, thermal necrosis during polymerization exothermy and 
stabilizing effect provided by cured cement 35. 
A “chemical effect” was postulated for pain relief as the most used bone 
cement for spine interventions is polymethylmetacrylate (PMMA) that contains 
a monomer component known to have toxic effects on cells36 and potential 
neurotoxicity37. Nevertheless this hypothesis is invalidated by the good clinical 
outcome recently demonstrated in a matched case-controlled study of 
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vertebroplasty with calcium phosphate cement (not containing any toxic 
monomer) compared with conservative treatment 38. 
Thermal necrosis of vertebral nerve endings due to PMMA polymerization 
exothermy has been also advocated in the past39 as a cause of pain relief on the 
basis of old papers, mainly aimed to investigate effects of large amounts of 
PMMA used to cement total hip prostheses, finding that cylinders with 
diameters from 5 mm to 30 cm can reach peak temperatures from 41° to 122°C 
during polymerization40. As previously reported in animal studies and often cited in 
papers about bone intervention, thermal necrosis in bone tissues occurs if 
temperatures >50°C are maintained for more than 1 minute 41 while injury to sensory 
nerves occurs at 45° C for more than 30 minutes 42. Some ex vivo studies have been 
done monitoring the temperature of PMMA and surrounding tissue during 
cement polymerization but these were performed on cadaveric specimens 
placed in saline bath heated at 37 °C that can just partially simulate the in vivo 
condition because don’t take into account the lowering of temperature caused 
by the convective effect of flowing blood and cerebrospinal fluid 39,43. 
Furthermore the simulated vertebroplasties were performed with bipedicular or 
bilateral (in the study from Belkoff et al. 43  pedicles were removed) injection 
of large amounts of PMMA that is quite far from current clinical practice: 10 
ml were injected in the study performed by Deramond et al. 39 and from 6 mL 
to 10 mL in the study from Belkoff et al. 43  
Additionally in an in vivo animal study 44 it was physiologically demonstrated 
that the local temperature did not reach values that are known to cause tissue 
necrosis but the average amount of PMMA injected (0.8 ml) was significantly 
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lower than commonly used in vertebroplasty. In this study PMMA contained 
only 13% barium sulfate as opacifier (25%–35% BA is the norm), the 
procedure was not performed percutaneously and the probes were placed only 
in the bone-cement interface.  
To date the only human in vivo measurement of polymerization temperature of 
several different bone cements was the one performed during the current PhD 
course and recently published by Anselmetti et al45. Eleven different bone 
cements were injected in 22 patients to treat 22 osteoporotic fractures with a 
monolateral approach. A radiofrequency thermal ablation (RFA) needle 
carrying five thermocouples, was than coaxially inserted through a 
vertebroplasty needle placed contralaterally. The hooks of the RFA needle 
were opened in order to deploy each thermocouple in a reproducible position as 
follows: within the anterior third (T5), and in the mid part of the vertebral body 
(T2), close to the superior (T1) and inferior (T3) endplates, and near the lateral 
left wall (T4). Consequently, thermocouples T2 and T5 were embedded in the 
cement, while T1, T3, and T4 were in the bone-cement interface. The amount 
of PMMA injected was 3 mL per vertebra while when using Cortoss (bis 
GMA) 2mL per vertebra were injected as this bone cement is reported to have 
higher cancellous bone perfusion rates compared to PMMA46.  
Using the average peak temperature values recorded during the study, the bone 
cements were categorized into three groups: Group A (Confidence and Mendec 
Spine), where the mean peak temperature value measured >60 °C; Group B 
(Osteopal V, Spinefix, Parallax, CementoFixx, Vertebroplastic, KyphX HV-R, 
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Osteofirm) with a mean peak temperature between 50 °C and 60 °C; and Group 
C (Ava-tex and Cortoss) with a recorded mean peak temperature <50 °C. 
Peak temperature values (always measured on thermocouple T2) for vertebrae 
injected with Confidence and Mendec Spine (Group A, 86.7 ± 10.7_C) were 
significantly higher (p = 0.0172; 95% CI, -43.523 to -8.834) than those injected 
with the PMMA bone cements categorized in Group B (60.5 ± 3.7_C) and 
those belonging to Group C (mean, 44.8 ± 2.6_C; p = 0.0047; 95% CI, -59.411 
to -24.339). A higher peak temperature was always measured on the 
thermocouples (T2 and T5) placed in the medial and anterior part of the 
vertebral body, where a higher concentration of bone cement was always 
delivered. 
Variation of median peak values among the bone cement groups was extremely 
significant (p = 0.0004, Kruskal–Wallis test). The average of all thermocouples 
showed an extremely significant temperature difference (p = 0.0002, Kruskal–
Wallis test) among Group A (median, 69.05), Group B (median, 55.60), and 
Group C (median, 44.40).  
While Cortoss and Ava-Tex (Group C) never reached 50 °C  every PMMA in 
Groups A and B showed an average dwell time longer than 1 minute (average 
of all, 2 min 25 s ± 1 min 17 s) potentially causing bone necrosis41, with the 
longer dwell time > 5 min recorded for Osteopal-V (average, 5 min 7 s ± 28 s). 
None of the tested bone cements maintained a temperature value of 45 °C for 
more than 30 minutes, which is necessary to achieve complete injury to the 
sensory nerves42  
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The results of this study suggest that thermal damage to intraosseous neural 
tissue and periosteal sensory nerves can be ruled out as the main mechanism in 
the clinical results of PV, such as pain relief. Furthermore the same clinical 
results are achieved using either relatively high-temperature PMMA (Groups A 
and B)34 or low temperature cements (Group C) as Cortoss 47,48. 
There are few case reports of hystologic findings in treated vertebrae 
documenting the necrotizing capabilities of PMMA: in one cadaveric specimen 
of a metastatic vertebra treated with vertebroplasty a necrotic rim up to 6 mm 
was found around PMMA 49 while, on the other hand in another cadaveric 
study performed on four vertebral specimens of two patients undergone both 
vertebroplasty (one vertebra) and kyphoplasty (three vertebrae) for 
osteoporosis the authors could identify only rare foci of necrosis in the 
harvested vertebral bodies, suggesting that if the feared thermal necrosis 
occurred during PMMA curing, most of the bone must have been remodeled by 
the time of specimen retrieval 40. A recent animal in vivo study showed the 
possibility of bone necrosis and no neural tissue necrosis at histology50 
Once “chemical effect” and “thermal effect” have been excluded or minimized 
as causes of denervation, the most probable mechanism of pain relief remains 
mechanical stabilization. 
Inner innervation of the vertebral body is provided by the basivertebral nerve, 
entering with the homonymous vein through the foramen of the posterior 
vertebral wall, and its roots within the trabecular bone up to endplates51. These 
nerve fibers have been found to produce substance P, which is strictly involved 
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in nociception, thus providing strong evidence that the vertebral cancellous 
bone itself can also be a source of pain52. 
Most of the pain due to a vertebral fracture should rely on the stimulation of 
vertebral nociceptors and substance P production. During fluoroscopic 
examination of a vertebral fracture is quite common to see endplate motion if a 
cleft due to osteonecrosis is present.  Mc Kiernan et al. perspectively 
investigated 50 patients under fluoroscopy, before vertebroplasty, finding 
fracture mobility with presence of a cleft in 24 of  them (48%)53. Typically 
patients with mobile fractures perceive pain during breathing, coughing or 
flexing the trunck depending on the fracture site. Pain should be mainly related 
to the motion of the endplates in Kummell’s disease (also because these are 
often the only surviving parts of the necrotic vertebral body) and to micro-
motion of trabecular fractures; both these conditions are common histologic 
findings in osteoporotic fractures54 This also explains the “miracle effect” of 
immediate pain relief after cement curing (also when low exothermy or 
anexothermic cement are used) that leads to stopping of the cleft motion after 
vertebroplasty or other vertebral augmentations. 
The variable amount of PMMA (from 2 to 6 ml) needed to be injected in a 
fractured vertebral body to obtain restoration of original biomechanical 
properties and thus provide pain reduction suggests the importance of a good 
mechanical stabilization in clinical outcome 55. 
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Even if a consensus has been reached between different societies of 
surgeons and radiologists giving birth to official guidelines on indications and 
contraindications, there are still differences in some technical aspects of 
theprocedure given by different learning curves, habits, skills or beliefs. 
There is no evidence of the utility of pre-procedural antibiotics and there are no 
studies on a better prophylaxis for vertebral augmentation. Some authors 
administer antibiotics intravenously during the procedure (usually Cefazolin) to 
all patients undergoing  spine percutaneous interventions while others do it 
only in immunocompromised patients23.  
Vertebral augmentation can be painful expecially during cement injection due 
to pressure increase inside the vertebral body. Procedures can be performed 
under local anesthesia (usually lidocaine or similar) administered 
subcutaneously  and over periostium, as it is well tolerated from most patients. 
Some authors perform spinal interventions during mild sedation and analgesia 
using fentanil and midazolam56 while others, expecially among surgeons, 
prefer endotracheal intubation and general anesthesia. 
Vertebral augmentation was initially performed with combined CT and 
fluoroscopic guidance57 (placing the portable C-arm in front on CT gantry) in 
order to precisely insert the needles taking advantage of CT and monitoring 
cement injection under fluoroscopy. With current technical skills aquired it is 
now possible to perform most of thoraco-lumbar vertebrae under fluoroscopic 
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guidance using CT guidance only for cervical levels, higher thoracic vertebrae 
and sacrum. Nowadays angiographic suites can aquire CT-like scans thus 
providing a better fluoroscopic guidance and CT advantages in a “all-in-one” 
machine58. 
To gain access to vertebral bodies to be treated, needles are usually introduced 
with transpeduncolar approach for lumbar levels and through costo-trasversary 
joints in thoracic levels. If the needle tip crosses the midline, unipedicolar 
approach in usually enough for vertebroplasty59 while for kyphoplasty a 
bilateral approach is required. For vertebral prostheses the approach can be 
unilateral or bilateral depending on the number of devices required per level. A 
biomechanic study by Tohmeh et al. showed no significant difference between 
unilateral and bilateral cement distribution in verteroplasty60. 
After the needle has been correctly positioned vertebral consolidation is 
performed by injecting bone cement, usually polymethylmetacrylate (PMMA), 
inside vertebral body. PMMA can interdigitate with trabeculae 
(vertebroplasty), can fill up a cavity formed after balloon inflation 
(kyphoplasty) or can surround vertebral endoprostheses.  
Biomechanical studies showed that an amount of PMMA equal to 2 ml per 
level is enough to restore strength and stiffness of the collapsed vertebra 55 
while too  high volumes can create excessive stiffness in the treated vertebra61 
Furthermore some authors found no relationship between the amount of bone 
cement injected and the clinical outcome5.  
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Pain relief and quality of life improvement 
- Immediate and short-term results 
Many clinical studies supported safety and effectiveness of percutaneous 
vertebroplasty in terms of pain relief and quality of life improvement 31,62-65.   
In a wide literature meta-analysis published in 2006 by Hulme et al. the results 
reported on 47 papers (about vertebral augmentations performed on 2958 
patients) have been compared; pain relief was reported in 87% of patients 
(1552 pts, 32 studies) in the papers where Visual Analogue Scale (from 0 to 
10) was used, VAS score dropped from a mean baseline value of 8.2  (666 pts, 
12 studies, 95% CI 7.8–8.6) to a mean post-operative value of 3.0 (95% CI 2.4 
–3.6)34. Pain relief is typically perceived immediately after procedure but in the 
following days is masked by post-operative pain and postural-adaptive 
muscular pain thus the optimal pain relief is experienced within a month.  
 
- Long term results 
Even if PMMA has been used in vertebroplasty for more than 20 years there is 
no scientific evidence of  very long term interactions with vertebral cancellous 
bone and stability of pain relief. There is lack of studies with long term follow 
up and, currently, no study with follow up longer than 5 years. Is also difficult 
to gather data for a ten-year follow up as the centers with such a long 
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experience are very few and furthermore osteoporotic patients have a high 
mean age (around 75 years old) while patients with bone malignancies have a 
poor five-year life expectancy. 
In the longer available follow-up (5 years) Perez-Higueras et al. reported, 
despite the limited population, that patients treated with vertebroplasty had a 
mean VAS score at baseline of 9.1±0.6 (mean±SD), that dropped to 2.1±1.1 
three days post procedure, 1.1± 1.1 after three months and at five years post 
procedure kept a value of  2.1±2.6 with a prolonged and statistically significant 
pain relief (p<0.001)66. 
Also in the prospective 3-year follow up study by Voormolen et al. 
performed on 112 patients treated with vertebroplasty, the clinically significant 
immediate pain relief was stable at one year and maintained significance on the 
third year of follow up 67. In this paper the median baseline VAS score was 9 
and dropped initially to a median value of 3 (within 24 hours) kept stable at 3-
month (median VAS score: 3) and dropped to a median value of 2 at 6-month, 
1-year and 3-year follow up; the same Authors made a literature meta-analysis 
of 14 similar perspective studies reporting a median baseline VAS score of 7.9 
that drops to 2.7 within 24 hours and remains substantially stable (3 and 2.9 
respectively) at mid-term  (3-6 month) and long-term follow up (1-3 year). 
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- New fractures 
In a wide perspective study performed by Lindsay et al. on 2752 
postmenopausal women treated with placebo it was found that among the 381 
patients who had a vertebral fracture 19.2% experienced a new fracture within 
a year (versus a cumulative incidence of 6.6%); thus a patient who already had 
a vertebral fracture has a 5-fold increased risk to experience a new fracture 
within a year while the risk becomes 7-fold if there are two collapsed levels 68.  
This “domino effect” makes part of the natural history of osteoporosis and in 
such a weak equilibrium the influence in the occurrence of new collapses of 
vertebral augmentation procedures has been long discussed with controversial 
proofs that percutaneous spine interventions are able to increase, decrease or 
leave unchanged the risk of new fracture if compared with conservative 
therapy.  
New fractures after percutaneous vertebroplasty are reported in the literature 
with an incidence ranging from 8% to 52% 69-71 making cause-effect 
relationship between new fracture, vertebroplasty and underlying osteoporosis 
controversial. The experimental study by Baroud et al.72 found an increased 
discal pressure after stiffening of vertebral fracture due to vertebroplasty 
leading to a potential higher stress on the endplate of adjacent vertebral bodies. 
 One of the first studies on the occurrence of  new fractures following 
vertebroplasty was published in 2000 by Grados et al. on 25 patients (out of 40) 
treated by H. Deramond from 1990 to 1996. These patients underwent physical 
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and spinal radiological examination in 1997 (mean follow up 48 months ±21 
ranging from 12 to 84 months) and in 13 patients (52%, complexively 34 
subsequent fractures were found) at least one fracture occurred with a slight but 
significantly increased risk of vertebral fracture in the vicinity of a cemented 
vertebra (odds ratio 2.27, 95% confidence interval 1.1-4.56).  Pain decreased 
from 80 ± 16 (VAS score from 0 to 100) to 37 ± 24 at one month and 37 ± 28 
at the long term follow up. Only one patient described no improvement in pan 
after the procedure. 
The high incidence of substantially asymptomatic fractures reported in this 
study may be significally affected by the small sample size, the high prevalence 
of secondary osteoporosis (9 pts: 36%), the wide range of follow up and the 
unknown ongoing medications.  
In a perspective study published by Voormolen et al. in 200673, osteoporotic 
patients treated with percutaneous vertebroplasty (PV) underwent follow-up 
MRI at 3, 6, and 12 months and 16 out of 66 patients (24%) where found to 
have 26 new vertebral fractures during the 1 year of follow-up. Most new 
vertebral compressive fractures (VCFs) occurred within 3 months of PV, half 
of new VCFs appeared in levels adjacent to treated levels, and half of the new 
VCFs were symptomatic. In this study, the presence of more than two 
preexisting VCFs was the only independent risk factor for the development of a 
new VCF. 
In a study published in 2008 by Hierholzer et al.74 316 patients were 
successfully treated (93% with pain relief) with PV for 486 “prevalent 
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fractures” (with bone marrow edema at MRI) and underwent a clinical follow 
up by phone interview 1 day, 7 days, 6 months, 1 year and, further on, on a 
yearly basis after vertebroplasty.  In the case of new onset or unsatisfactory 
relief of back pain, patients were reinvited and physical examination as well as 
MRI using STIR sequences were performed.  During follow-up period (mean 
follow-up: 8 months; range: 6–56 months) 16.4% of the patients (52 out of 
316) returned with 69 symptomatic incidental fractures with bone marrow 
edema at MRI. In this study, incidental new VCFs were adjacent to previously 
treated fractures in 51% of cases with no statistically significant difference 
versus distant VCFs. The most frequent site of new VCFs was thoraco-lumbar 
junction (cluster: T11-L2) this was both statistically significant for baseline 
fractures (p>0.02) as well as for new fractures (p>0.05, v2 test). However, no 
statistically significant difference in the fracture localization between prevalent 
and incidental VCFs was found as if anatomy and underlying osteoporosis play 
a key role in the occurrence of new VCFs. 
 
Complications 
Vertebral augmentation procedure can be currently considered safe as the most 
recent meta-analysis on vertebroplasty and kyphoplasty found a low morbidity 
and mortality rate of both procedures34,75.  
The most serious adverse events can be neurological complications, due to 
wrong needle pathway and/or PMMA leakage, or pulmonary complications 
that are mainly due to bone cement venous leakage. 
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Pulmonary embolism (PE) of bone cement is the most frequent complication, 
reported from 3.5% to 23%76, that in most cases occurs without significant 
symptoms as PMMA is not thrombogenic and the amount of cement embolized 
to lungs is too low to determine clinical symptoms. The high rate of PE 
detected by Kim et al. (23%)77 in patients undergone vertebroplasty and 
systematically screened with post-operative chest CT lead to state that the real 
occurrence of embolic complications is underestimated.  
Even if overall morbidity is low, vertebral augmentation procedures can be 
potentially harmful as among major complication have been described epidural 
hemorrage leading to paraplegia 78, intradural cement leakage79, lethal 
pulmonary embolism80 and spondylitis81,82.   
  
 
- Vertebroplasty vs placebo  
In 2009 two randomized studies appeared in the New England Medical Journal 
comparing vertebroplasty with a sham procedure 83,84 concluding that 
vertebroplasty might have a placebo effect. These papers, published 
simultaneously in the same important journal cast doubts on a procedure that, 
since then, was believed to be effective and safe in providing pain relief for 
symptomatic vertebral fractures.  INVEST study, coordinated and published by 
Kallmes83, was a randomized study comparing vertebroplasty (68 patients) 
versus a control intervention called “sham procedure” (63 patients). Inclusion 
criteria were painful (VAS>3) osteoporotic vertebral fractures (< 1yr) with one 
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year follow up. The 131 enrolled patients were blinded to the procedure. The 
control arm underwent pedicle local anesthesia, and during the “sham 
procedure” were made to believe they underwent the real vertebroplasty 
(verbal and physical simulations were made pretending to perform the 
procedure and the methacrylate monomer was opened to simulate the odor of 
PMMA mixing). The patients had the chance to cross-over to the other arm 
after one month and up to three months after the first procedure. The primary 
clinical outcome was assessed with Roland-Morris Disability Index and 
perceived pain rated with VAS (0-10) while secondary outcomes were assessed 
with other questionnaires (Pain Frequency Index, Pain Bothersomeness Index 
SF 36, SOF–ADL, EQ–5D) and analgesic use; measurements were made at 3 
days, two weeks, 1 and 3 months. INVEST study concluded that clinical 
improvement (at 3 days and 1 month), in patients with painful osteoporotic 
vertebral fractures, was similar among those treated with vertebroplasty and 
those treated with a simulated procedure. The study from Kallmes et al. have 
many drawbacks, first of all the main intent: the “sham procedure” is closer to 
a facet block than a placebo and doesn’t represent the real alternative to 
vertebroplasty that, in clinical practice, is conservative treatment.  
There is a selection bias of such studies because patients with severe pain are 
unlikely to agree to randomization of a popular intervention versus a fake 
procedure and there is a further selection bias in this study because, due to the 
slow recruitment (131 pts enrolled among 1813 screened in 11 sites in US, UK 
and Australia during a 4-year period),  inclusion criteria were broaden even 
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further to include patients with VAS score of 3. At three months 43% of 
patients that had undergone the sham procedure had crossed over to 
vertebroplasty versus 12% of subjects belonging to vertebroplasty arm that had 
crossed over to the sham arm (p<0.001). “This crossover was the most 
statistically significant observation in the trial” as stated by Prof. Joshua A. 
Hirsch in his lecture: “Vertebral Augmentation Procedures in a post RCT 
world” presented at GRIBOI Meeting 2010 held in Torino (Italy)85 who 
furthermore raised concerns about the reliability of patient blinding considering 
that 74% of patients in control group who guessed correctly (patients were 
asked to guess which procedure they underwent) and 75% of patients in PV 
group who guessed incorrectly crossed over to the other group.  
Furthermore nor clinical examination nor bone marrow edema on MRI were 
used for patient selection and during follow up (rather relying on complex 
questionnaires and plain radiographs) and occurrence of new fractures was not 
investigated as a possible cause of pain during follow up.  
In the “Australian” multicentric randomized controlled study by Buchbinder et 
al.84 78 patients with osteoporotic fractures were recruited (versus 468 screened 
in 4.5 years and 141 found eligible who declined randomization) and randomly 
enrolled into the vertebroplasty arm (38 pts) and a placebo arm (40 pts; placebo 
was represented by a pedicle local anesthesia followed by a 13G vertebroplasty 
needle placement on periostium). Inclusion criteria were back pain duration 
less than 12-months and the presence of one or two recent vertebral fractures 
(edema and/or a fracture line within the vertebral body on MRI were imaging 
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inclusion criteria). 
Primary outcome was overall pain as measured by VAS score (0-10) at 3 
months.  This study found no significant benefit of vertebroplasty over a sham 
procedure during 6 months of follow-up among patients with recent 
osteoporotic vertebral fractures. The Australian trial also showed some flaws 
such as: the small sample size with possible selection bias, no clinical 
examination, uncertain MRI inclusion criteria, a very high predominance of 
one center (67% out of 4 centers, two of them enrolled five patients each) in a 
so called “multicentric study”. Both the studies were published without any 
invited commentary and without any pre-procedural and post-procedural 
imaging. 
In this era where only Evidence Based Medicine seems to rule, the 
simultaneous publication of two randomized controlled trials about the same 
debated topic on the same world famous journal triggered a chain reaction from 
media to public opinion and from professional boards to insurance companies.  
A bill passed by American Congress in 2009 provided $1.1 billion for such 
comparative effectiveness research86 and these new studies are exactly the kind 
of research that health policy experts and President Obama government have 
been calling for to get rid of medical treatments of unproven efficacy.  
The news about “vertebroplasty found to be useless for vertebral fractures” was 
reported by several newspapers, from New York Times87 to Corriere della 
Sera88, and internet blogs89 with opinions that were in some case more critical 
and in some others categorically agreed with trial conclusions. 
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This background led some insurance companies90 to consider denial for 
reimbursement of vertebroplasty and other vertebral augmentation procedures 
and some law firms91 to take advantage of the bad reputation of these 
interventions to seek patients who want to sue their surgeons for treating them 
with bone cement. Professional boards and societies took different positions 
toward percutaneous spinal interventions: American Academy of Orthopaedic 
Surgeons (AAOS) strongly recommend against vertebroplasty92 for patients 
who present with an osteoporotic spinal compression fracture on imaging with 
correlating clinical signs and symptoms (while accepts kyphoplasty with 
Strength of Recommendation: Weak) while Society of Interventional 
Radiology expressed criticism against the trials defending the value of 
vertebroplasty.93 
 
- Vertebral height increase  
Vertebral body collapse leads to hyperkyphosis which entirely depends upon 
the number and the severity of  wedge fractures. This painful condition can  
provoke a reduction of the pulmonary function and may lead to further 
fractures 94,95.  
Based on the background of kyphoplasty an endoprosthesis device has been 
designed and developed not only to relieve pain but to reduce kyphosis. 
Vertebroplasty is also able to restore vertebral height 96,97  expecially in 
Kummell’s disease and in mobile fractures where is able to obtain a vertebral 
height gain up to 9.6 mm. Usefullness of height restoration is still debated 
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because even if vertebral height gain is considered statistically significant in 
the above cited studies, clinical relevance of kyphosis correction has already to 
be scientifically proven.  
In a small case series from McKiernan et al comparing vertebroplasty with 
vertebral height restoration (average gain: 2.9 mm. up to 9.6 mm) and without,  
both groups had a comparable pain relief with no significant difference in 
terms of quality of life assessed by means of Osteoporosis Quality of Life 
Questionnaire (OQLQ) 98. As the authors admit “perhaps the outcome 
instruments were insensitive to an important clinical benefit of vertebral height 
restoration that thereby went unrecognized”. Respiratory function 
improvements were not investigated as usually is in most of studies regarding 
vertebral augmentation. These results may suggest that questionnaires are 
inadequate to evaluate clinical relevance of vertebral augmentation rather than 
invalidate its utility. 
 
- Vertebroplasty and Kyphoplasty vs conservative treatment 
 
The treatment for osteoporotic spinal compression fracture before spinal 
interventions were introduced was conservative therapy (bed rest, pain 
medication, brace support) and, still representing the only current alternative to 
such treatments, this should be compared to vertebral augmentation procedures 
rather than a placebo. 
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Even if considered a safe non-intervention, also conservative treatment also 
carries some risks, as prolonged bed rest can cause deep vein thrombosis, bone 
loss (bone density decreases by 2% per week and even more in osteoporotic 
patients)99, decreased cardiac reserve, muscular weakening (muscle strength 
decreases up to 10%-15% per week)100  gastrointestinal (reduced appetite and 
constipation) and respiratory complications (decreased airway clearance and 
atelectasis with predilection for pneumonia)101.  
Furthermore the discomfort of brace support and the side effects of opioids 
must be taken into account in a fragile population such as older female patients. 
The first perspective non randomized controlled trial of vertebroplasty versus 
conservative treatment was performed in 2006 by Diamond et al.102; this paper  
compares pain relief in 88 patients that had Vertebroplasty and 38 patients 
treated conservatively. The vertebroplasty group obtained pain relief that was 
significant higher than the conservative care group at 24 hours and at 6 weeks; 
this difference lost significance at 1-year and 2-year follow up. Between the 
two groups there was no statistically significant difference in new fracture 
rates.  
The main flaw of this study was not to be randomized thus only the few  
patients who refused vertebroplasty (38 vs 88) were conservatively treated; 
furthermore the enrolled patients had recent fractures (1-2 weeks) and weren’t 
previously treated with conservative treatment as commonly suggested in 
vertebroplasty indications. The study by Diamond et al. rather than invalidating 
the effectiveness of vertebroplasty strengthen the importance to treat patients 
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when conservative therapy fails as fractures can heal by themselves in the long 
period. On the other hand, vertebroplasty gifted to a fragile old aged population 
some pain-free months (up to one year) without the sequelae of prolonged 
inability and discomfort of brace support  
In 2009 Lancet published the 1-year results of the ongoing 2-year follow-up 
FREE trial 103 and in 2010 the results of VERTOS II104; both were multicenter 
randomized controlled trials comparing conservative treatment respectively to 
kyphoplasty (FREE)  percutaneous vertebroplasty (VERTOS II). 
The FREE trial involved 28 sites in 8 European countries enrolling 300 patients 
that were randomized to kyphoplasy or conservative treatment (149 BKP vs 
151 NSM) with a one year follw up (1, 3, 6, 12 month f/u). 
Inclusion criteria were 1 to 3 acute VCFs (at least 1 VCF with edema on MRI 
and one with ≥ 15% vertebral body height loss),  and VAS score ≥ 4.  
Conservative Treatment was performed according to hospital protocol with 
pain medication, bed rest, walking aids, brace support and physiotherapy. 
The primary endpoint was to assess the change in SF-36 PCS (Physical 
Component Summary) at 1 month between the two groups. 
Secondary endpoints (at 1, 3, 6 and 12 months) were SF-36 subscales (scale 0–
100), EuroQol-5D (EQ-5D) questionnaire , VAS score (0-10),  Roland-Morris 
scale (0-24-point), restricted activity days and bed rest due to back pain in the 
previous two weeks, analgesic use and adverse events assessment. 
This randomized controlled trial showed, with a Level 1 clinical evidence, that 
in patients with acute symptomatic vertebral fractures, balloon kyphoplasty 
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improved quality of life, function, mobility, and pain more rapidly than did 
conservative treatment, with significant differences in improvement between 
the groups at 1 month. For most outcome measures, the differences between 
the two groups were diminished at 12 months because the non-surgical group 
improved over time, probably as a result of fracture healing. 
No deaths related to kyphoplasty occurred and BKP showed no difference in 
frequency of adverse events compared to the non-surgical group. 
Kyphoplasty group did not show a significant increase in new radiographic 
vertebral fractures at 1 year compared with the control group. 
Patients in the kyphoplasty group therefore had a better quality of life during 
the year following the fracture due to faster healing, less narcotic use and 
quicker return to activity. 
The VERTOS II trial involved  five large teaching hospitals in the Netherlands 
and one in Belgium finding 431 patients eligible for participation in the 
randomized trial (between October 2005 and June 2008), 202 of whom, who 
had persistent pain, were randomly referred to vertebroplasty (101) or 
conservative treatment (101). Main inclusion criteria were: vertebral 
compression fracture (T5 to L5) on spine radiograph (minimum 15% height 
loss) with bone marrow edema on MRI, VAS ≥ 5, focal tenderness at fracture 
level, and decreased bone density (T scores ≤–1).  
The primary outcome was pain relief at 1 month and 1 year, measured with a 
VAS score (0-10) while the secondary outcome was cost-effectiveness at 1 
month and 1 year and the tertiary outcome was quality of life measured with 
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QUALEFFO questionnaire105 and physical function measured with the Roland 
Morris Disability questionnaire. 
Vertebroplasty provided a greater pain relief compared to conservative 
treatment; difference in mean VAS score between baseline and one month was 
-5.2 after vertebroplasty and -2.7 after conservative treatment, and between 
baseline and one year was -5.7 after vertebroplasty and -3.7 after conservative 
treatment. The difference between groups in reduction of mean VAS score 
from baseline was 2.6 at one month and 2 at one year. 
It is noteworthy that more than half of the patients who initially qualified for 
the study had a spontaneus decrease of the perceived pain with a VAS score 
lower than 5 thereby precluding inclusion. In conclusion, in a selected 
subgroup of patients with acute osteoporotic vertebral fractures and persistent 
pain (unresponsive to initial conservative management) vertebroplasty has 
shown to be effective and safe providing immediate and durable pain relief. 
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  Vertebral augmentation with nitinol endoprosthesis: 
clinical experience with one year follow up in 40 patients 
 
Aim  
To assess safety, effectiveness and vertebral height restoration of 
endoprosthesis-assisted vertebroplasty during long-term follow-up 
 
 
Materials and Methods 
 
Between December 2008 and September 2009, 40 consecutive patients 
(36 females, mean age 73.6 ± 8 years, range: 55-86 years,) were treated with 
percutaneous vertebral augmentation performed by placement of 84 nitinol 
prostheses (two devices were positioned in each vertebra and 2 patients were 
treated for two fractures in the same session). 
 
- Patient selection 
 
A pre-procedural consultation was arranged with all patients in order to 
perform a physical examination, to gather imaging and anamnestic issues 
useful to find a correlation between symptoms, history and imaging findings, 
and to explain benefits and risks of vertebral augmentation.  
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Inclusion criteria were as follows:  
- 55 years or older 
- A1.1, A1.2 or A1.3 compression fractures according Magerl’s A.O 
Fracture Classification  
- Bone marrow edema within the fracture assessed with MRI (performed 
with fat suppression sequences) 
- Significant back pain (Visual Analogue Scale score: 5 or higher) 
-  Tenderness to palpation over the spinous process of the fractured vertebra 
- Minimum of 4 weeks of conservative treatment (bed rest, brace support,, 
analgesic therapy) 
 
Exclusion criteria were as follows:  
- A2, A3, B and C vertebral fractures according Magerl’s A.O. Fracture 
Classification 
- Systemic infection or any suspicious infective spondylodiscitis 
- Uncorrectable coagulation disorders 
- Healed fractures without bone marrow edema 
- Unspecific or mild back pain (VAS: 4 or lower) 
- Nerve root pain or neurologic deficit due to the fracture 
- Poor general conditions (Karnofsky score < 50%, ECOG >3) 
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All interventions were performed in the angiographic room equipped 
with machinery capable of both fluoroscopy and CT-like multiplanar 
reconstructions obtained by acquiring the desired body volume with rotation of 
the C-arm working as a cone beam CT (Allura Xper CT; Philips).(Fig. 1e) 
Monitoring of patient’s heart rate and pulse oximetry were carried out 
continuously throughout the procedure and blood pressure was monitored 
externally and recorded automatically every 5 minutes. Continuous assistance 
to the patient was offered during the procedure by a trained nurse. When 
necessary the patients were asked by the interventional radiologist about the 
features of perceived pain (eventual nerve shock sensations) and sensitivity and 
mobility of lower limbs in order to further rule out nerve damage. 
All procedures were performed with local anesthesia by injection of no 
more than 1.5mL of 2% Lidocaine hydrochloride (Lidosan, Industria 
Farmaceutica Galenica Senese, Monteroni d’Arbia, Siena, Italy) per needle 
administered subcutaneously and over pedicle periostium.  Lidocaine was 
administered using a 22 G quincke needle positioned under fluoroscopic 
guidance in “the eye of the Scottie dog” for lumbar levels or through the 
costotrasversary joint for thoracic levels following the desired transpeducular 
or costotrasversary path of the vertebroplasty needle. Access needles were 
inserted using the described radiologic landmarks in the oblique projection and 
Antonio MANCA - Vertebral Augmentation with Nitinol Endoprosthesis: Clinical Experience  with one year 
follow-up in 40 patients 
Tesi Dottorato in Scienze Biomediche – Università degli Studi di Sassari 
40 
then advanced in the Antero-Posterior projection in order to reach the medial 
aspect of the pedicle. 
A CT scan was then performed in order to assess the correct needle path 
and to measure pre-procedural vertebral height. (Fig. 1c, 3c, 3d) When the 
needles were in the correct position, the pathway for the implant was created 
using a coaxial manual drill (Fig. 1d).  
Bone tissue removed during drilling was gathered for histological 
examination as a coaxial tru-cut biopsy is routinely performed in all bone 
interventions at our institution, to determine underlying pathologies, including 
malignancies.  
The implant delivery systems (SpineAlign VerteLift™ System; San 
Jose, CA, USA) were then introduced through the cannula and the nitinol 
implants were manually opened using the handle attached to the delivery 
system (Fig. 2e) and adjusted under fluoroscopy until an “XX” fashion in the 
AP projection was obtained (Fig. 2b, 2d) in order to allow device struts to lift 
the vertebral endplates and restore vertebral height. 
Once the implants were properly positioned and fully expanded, the 
delivery system was detached. (Fig 2c, 2d) 
Injection cannulae were pre-filled with polymethylmethacrylate 
(PMMA; KyphX HV-R®; Elmdown LTD. London, England) and, when bone 
cement reached a “toothpaste consistency”, were coaxially advanced through 
the working cannulae up to the distal end of the implant. Cement injection was 
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performed, under continuous fluoroscopic guidance, emptying the prefilled 
cannulae with a manual blunt tip pusher. (Fig. 3g) 
An average amount of 5 mL of thickened PMMA was injected per level;    
injection was stopped when a satisfactory vertebral replenishment was 
obtained, or in case of significant leakage. 
Once the injection was over and the needles withdrawn, a CT scan was 
performed in order to repeat vertebral measurements, rule out complications 
and detect any leakage. (Fig 3e, 3f) 
 
- Device  
The endovertebral prosthesis used in this study was a Nitinol cage 
(VerteLift™, SpineAlign Inc. San Jose, CA USA). Nitinol is a proven 
biocompatible Nickel-Titanium alloy commonly used in interventional 
radiology for decades which has a unique combination of shape memory and 
super-elasticity properties. 
The implant struts are designed to flex against endplates and obtain a broad 
pressure distribution, without a single point contact, thus avoiding endplate 
damage. Nitinol returns to its original shape after repeated, large deformations 
and the VerteLift™ implant showed resistance to subsidence demonstrated at 
3000N for five million cycles with a static compression that resulted in 4-fold 
to 5-fold greater than the maximum physiologic loads. 
Pressure exerted in biomechanical tests by an asymmetric 18 mm VerteLift 
implant was 3.3 MPa, thus strong enough to shift endplates (pressure to shift 
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healthy bone is 2.5MPa while pressure to shift osteoporotic bone is 1.25MPa) 
and significantly below the pressure level required to fracture an endplate 
(pressure to fracture healthy bone is around 8MPa while pressure to fracture 
osteoporotic bone is around 4MPa). 
The VerteLift implant is designed to be collapsed and expanded multiple times, 
if repositioning is required, and can also be safely retrieved and withdrawn 
through the cannula (also when completely expanded and released) if removal 
is necessary. 
 The implants used in the study were in asymmetric and symmetric shapes with 
16 mm and 18 mm diameters (identical to commercially available ones, 
currently available also in 14 mm and 20 mm sizes). 
 The implant size and shape chosen were based on fracture shape and vertebral 
body size; a given implant could be replaced with a different size or shape, 
even after expanding in the vertebral body, if it did not fit the vertebral fracture 
that was being treated.  
The nitinol implant is mounted on a delivery system that allows, in the closed 
fashion, its insertion through the 4.8 mm working cannula and through the 
channel made with the manual drill inside the vertebral body. The delivery 
system is mounted on a handle (the one used in our experience was the 
“amber” reusable prototype) that, with a simple manual screw/rotate/unscrew 
mechanism allows opening, positioning and closing of the prosthesis. 
The VerteLift System for vertebral augmentation included an access kit (two 
4.8 mm needles/working cannulas with beveled tip and a manual drill) and 
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some injection cannulae with tapered ends designed to be inserted in the 
working cannulae and through the implant up to its distal part. Blunt tip 
pushers of two different sizes were also included to empty both the large 
proximal part and the tapered distal end thus delivering approximately 1.6cc of 
bone cement per cannula.  
 
- Radiological assessment and vertebral height measurements 
 
Vertebral height was measured immediately before and after vertebral 
augmentation in order to assess vertebral height restoration. 
For pre-procedural and post-procedural measurements, CT-like 
multiplanar reconstructions were obtained by the angiographic equipment. 
Six measurements were taken for each treated level: three in the mid-
coronal reconstruction (left, central and right) and three in the mid-sagittal 
reconstruction (anterior, central and posterior). 
A standard CT scan (LightSpeed16; General Electric. Milwaukee, 
U.S.A.) was performed one year after the procedure to check implant position 
and integrity and to repeat measurements with MPR reconstructions 
(Advantagewin 4.2; General Electirc). CT scan field of view included one level 
above and one below the treated fractures. 
On the same day a standing plain radiogram of the spine was taken to 
assess spine alignment, fracture stability and new fractures on the 
thoracolumbar spine. 
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All of the CT measurements and plain film evaluations were made by 
two independent radiologists blinded to clinical outcomes. 
 
- Pain and Quality of life assessment  
Patients were asked to rate their perceived pain using a visual analog 
scale (VAS) on a 0-10 scale at baseline (the day of the intervention), after the 
procedure (within 24 hours) and after one year. A VAS score post-procedural 
reduction of at least 2 points was considered significant. 
Analgesic drug use was rated from 0 to 4 as follows: 0 for no drugs, 1 
for Non-Steroidal Anti-Inflammatory Drugs (NSAID), 2 for oral narcotics, 3 
for transdermal opioids, 4 if opioids were administered intravenously. 
Quality of Life (QoL) was assessed using the Oswestry Disability Index 
(ODI) questionnaire at the time of clinical interview before the procedure, two 
weeks after the procedure and one year after the procedure.  
 
- Statistic analysis 
 
Raw data for CT measurements, VAS scores, and ODI scores performed 
at baseline, immediately after the procedure and at the one year follow ups 
were analyzed with InStat 3 software (GraphPad;, San Diego, CA-USA) 
designed for Mac. 
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All VerteLift™ implants were successfully positioned in all patients. No major 
complications or peri-operative deaths occurred. No venous PMMA bone 
cement leakages were detected with fluoroscopy during the procedure or with 
post-procedural CT scans. 
Mild asymptomatic cement leakages were detected in four out of 42 treated 
levels: one was para-pedicular and three were inside the vertebral disc. The 
overall leakage rate was 9.5% while discal and venous leakage rate were 7.1% 
and 0% respectively.  
Vertebral height was significantly increased (restored) (p<0.0001 paired t-test) 
at immediate post-operative measurements: average height gain (millimeters) 
in mid-coronal MPR reconstruction were 2.4 ±2.4 (left), 3.9 ±3.0 (center), 1.6 
±1.9 (right) and in mid-sagittal MPR reconstruction were 2.3 ±2.3 (anterior), 
4.7 ±3.6 (center) and 1.9 ±2.2 (posterior) (very significant p=0.0026). 
Perceived back pain reduced from a baseline value of 8.0 ± 1.6 SD to a mean 
VAS score of 0.7 ± 1.4 SD within 24 hours, obtaining a mean differential VAS 
score of 7.3 ± 1.7 SD that was statistically significant (p<0.0001, Wilcoxon 
test). Immediate pain relief was obtained in all patients but one (patient # 30) 
with an overall pain improvement of 97.5% within 24 hours.  
Oswestry Disability Index (ODI) had a mean value of 6.5% ± 13.7% SD two 
weeks after the procedure versus a baseline mean value of 69.7% ± 16% SD 
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with a differential mean value of 63.2% ± 18.4% SD. Quality of life had a 
statistically significant improvement at short term follow up (p<0.0001, 
Wilcoxon test). 
Patients were thereafter contacted by phone in order to arrange a clinical 
evaluation (with VAS and ODI assessment) and a radiological evaluation 
(standing plain radiogram of the spine and spine CT). Mean follow up was 15 
months ± 2.0, ranging from 11 to 21 months. 
 
Follow up has been completed in 38 of the 40 (95%) patients. One patient 
(#30) who had undergone vertebral augmentation on L5 with incomplete pain 
relief, required surgical fixation for an underlying mild lystesis and therefore 
did not complete the follow up. One patient (#22) died after six months for 
heart failure, thus no deaths related to the procedure occurred during follow up.  
 
ODI obtained at baseline, at 15 days and at 1-year follow up and VAS scores at 
baseline, within 24 hours and at 1-year follow up were compared with Dunn's 
Multiple Comparisons Test.  
A statistically significant difference was confirmed between pre-procedural and 
post-procedural ODI and VAS scores.   The difference between pre-procedural 
and 1-year follow up values were also significantly different. The difference 
between post-procedural and 1-year follow up pain relief and quality of life 
scores were not significant thus meaning that benefits provided by vertebral 
augmentation were long-lasting and stable.  
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In Dunn’s Multiple Comparison Test, if the difference between rank 
sum means is greater than 21.420 the p value is considered less than 0.05.  
P value >0.05 was considered not statistically significant. 
P-value <0.01 and p-value <0.001 were considered, respectively, significant 
and extremely significant. Rank sum differences and corresponding p-values 
for each measurement are summarized in the tables below. 
 
Oswestry Disability Index 
Comparison Rank Sum  Difference p-value 
ODI pre-op vs. post-op 59.000 p<0.001 
ODI pre-op vs. 1 year 53.500 p<0.001 
ODI post-op vs. 1year -5.500 p>0.05 
  
   
Visual Analogue Scale  
Comparison Rank Sum  Difference p-value 
VAS pre-op vs. post-op 59.000 p<0.001 
VAS pre-op vs. 1 year 53.500 p<0.001 
VAS post-op vs. 1 year -5.500 p>0.05 
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Pre-procedural, post-procedural and long term follow up CT measurements 
were compared with Dunn's Multiple Comparisons Test concluding that there 
is a statistically significant difference between all pre-procedural and post-
procedural measurements, between all pre-procedural and long-term follow up 
measurements while there is no statistically significant difference between any 
post-operative and long-term follow up measurements. These data lead to our 
conclusion that we obtained significant increases in vertebral height  that were 
substantially stable over the reported time periods , with no significant height 
loss during long term follow up. Rank sum differences and corresponding p-
values for each measurement are summarized in the tables below. 
 
Vertebral height measurements in MPR Mid-Coronal reconstruction: 
Comparison (see table 3) Rank Sum  Difference p-value 
Left pre-op vs. left post-op -37.000 p<0.001 
Left pre-op vs. left 1 year -32.000 p<0.01 
Left post-op vs. left 1year 5.000 p>0.05 
 
Comparison (see table 4) Rank Sum  Diff. p-value 
Center pre-op vs. center post-op -56.000 p<0.001 
Center pre-op vs. center 1 year -52.000 p<0.001 
Center post vs. center 1 year 4.000  p>0.05 
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Comparison (see table 5) Rank Sum  Diff. p-value 
Right pre-op vs. right post-op -35.500 p<0.001 
Right pre-op vs. right 1 year -36.500 p<0.001 
Right post-op vs. right 1 year -1.000 p>0.05 
 
 
Vertebral height measurements in MPR Mid-Sagittal reconstruction: 
 
Comparison (see table 6) Rank Sum  Diff. p-value 
Anterior pre-op vs. ant post-op -35.500 p<0.001 
Anterior pre-op vs. ant 1 year -39.500 p<0.001 
Anterior post-op vs. ant 1 year -4.000 p>0.05 
     
 
Comparison (see table 7) Rank Sum  Diff. p-value 
Center pre-op vs. center post-op -55.000 p<0.001 
Center pre-op vs. center 1 year -47.000 p<0.001 
Center post-op vs. center 1 year 8.000  p>0.05 
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Comparison (see table 8) Rank Sum  Diff. p-value 
Posterior pre-op vs. poster. post-op -34.500 p<0.001 
Posterior pre-op vs. poster. 1 year -30.000 p<0.01 
Posterior post-op vs. poster. 1 year -4.500 p>0.05 
 
    
During follow-up no device change or migration was observed.  
In follow-up, six patients had new fractures with an overall fracture rate 
of 15% but as pt. # 2 had an high energy trauma (fell from the stairs) two 
weeks after vertebral augmentation and pt. #19 was found to have an 
underlying Multiple Myeloma (after biopsy) only four must be considered as 
spontaneous osteoporotic new fractures with a new fracture rate of 10%. Three 
fractures were detected on the levels above the treated vertebra (all 
spontaneous) and three on the level below the treated vertebra (including one 
spontaneous, one traumatic and one in the patient with myeloma).  
VerteLift didn’t show any significant artifact at MRI (patient #23 
performed MRI at 1-year ). (Image 4) 
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Vertebral augmentation performed with the VerteLift implants was safe as no 
major complications related to the procedure occurred during the intervention 
and at 1-year follow up. VerteLift implant was retrievable and repositionable 
whenever necessary and the 84 implanted devices exhibited no change in 
position or morphology over a follow up period up to 21 months. 
There is lack of published data about vertebral implants but occurrence of 
implant migration is not likely to happen as, despite the few cases performed 
worldwide, a single adverse event was reported in FDA MAUDE database for 
delayed migration of a Staxx FX (Spine Wave, Shelton, CT, USA) three 
months after intervention causing back pain and requiring surgery 106.  
As routine vertebral augmentation is designed to be entirely performed with a 
percutaneous access, and a large number of these interventions are performed 
by interventional radiologists, an important goal is to minimize complications 
requiring surgical revision as a result of failed detachment of the device and 
malpositioning or migration of the implant.  
The VerteLift procedure was demonstrated to be safe in terms of venous 
leakages. In our experience venous cement leakage never occurred.  This 
indicates that is possible to obtain vertebral augmentation with an optimal 
safety profile and predictable low cement leakage without compacting 
cancellous bone.  
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This method of vertebral augmentation was extremely effective in terms of 
immediate pain relief and quality of life improvement for patients following 
vertebral compression fractures considering that mean pre-op/post-op VAS and 
difference was 7.3 ± 1.3 and the mean ODI difference between pre-operative 
value and 2-weeks follow up was -63.2% ± 18.4%. The improvements in VAS 
and ODI scores, both clinically significant, didn’t show statistically significant 
changes over one-year follow up period thus meaning that a durable reduction 
of symptoms was achieved. 
Vertebral augmentation performed with VerteLift has demonstrated safety and 
effectiveness (in terms of pain relief and QoL improvement), which constituted 
the main endpoints of this study. These results are comparable with traditional 
vertebral augmentation procedures such as vertebroplasty and balloon 
kyphoplasty. 
The Nitinol VerteLift implant has the theoretical advantage to prevent loss of 
vertebral height intraoperatively and post-operatively over time by exerting an 
endplate to endplate lifting that is sustained during bone cement injection and 
is permanently mantained after polymerization while in kyphoplasty, the 
vertebral height restored during augmentation, can be lost after balloon 
deflation due to elastic recoil. 
In this study, most of the restored vertebral height was measured in the central 
point of the endplates. Highest gains were found in the central measurement 
taken in mid-coronal (3.9 mm  ±3.0 SD) and in mid-sagittal reconstruction (4.7 
mm  ±3.6 SD). 
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Vertebral height restoration was kept stable by the cemented nitinol implant. 
No statistically significant height loss, in any  of the six anatomic measuring 
points was detected  during one-year follow-up measurements. Height loss 
could be an issue in other vertebral augmentation procedures as both in 
kyphoplasty107 and vertebroplasty108 have already been reported in the 
literature. 
A comparative trial involving balloon kyphoplasty and a metallic implant made 
of titanium (OsseoFix™, Alphatec Spine Inc., Carlsbad, CA, USA)109 was 
performed in a biomechanical in vitro study. Significantly greater vertebral 
height loss (P <0.025) was detected after recompression of kyphoplasty repair 
(0.29 ±0.12 cm versus 0.20 ± 0.11 cm) compared to the titanium mesh implant. 
The biomechanical properties (yield load, ultimate load and stiffness) of the 
two repair techniques were not found to be statistically different while the 
amount of bone cement required for the OsseoFix procedure was less than for 
kyphoplasty and  cancellous bone was more likely to be preserved as 4 of 48 
repaired vertebrae demonstrated significant damage by the Kyphoplasty 
balloon procedure.  
The VerteLift implant, compared to OsseoFix, should provide endplate-to-
endplate lifting with potential greater height restoration, lower height loss over 
time with the additional significant value of complete retrievability and ability 
to be repositioned as often as necessary to achieve optimal vertebral 
reconstruction.   
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Compared to kyphoplasty the placement of nitinol implant provided vertebral 
height restoring partially preserving cancellous bone; cement interdigitation 
through trabeculae therefore allowed to inject an average amount of 5 mL 
PMMA instead of the 8 mL required to fill the cavity created by two 4cc 
kyphoplasty bone tamps. This wa an important feature as the amount and the 
distribution of bone cement has a significant correlation with the incidence of a 
subsequent vertebral fracture 110 
The incidence of new spontaneous vertebral fractures was 10% (the post-
traumatic high energy fracture and the fracture in the patient found with an 
underlying Myeloma were excluded) that can’t be compared with statistical 
significance with conservative treatment or any other procedure as we didn’t 
have any control group but this percentage lays in the low values of the range 





Vertebral augmentation performed with the VerteLift nitinol implant is a 
safe and effective procedure able to provide a long-lasting pain relief and a 
persistent vertebral height gain. Furthermore the nitinol implant allowed to 
obtain an optimal trabecular perfusion of bone cement, due to preservation of 
cancellous bone, without the occurrence of venous leakages.  
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Table 1: Patients demographics (pt # 1 to 20), VAS (Pre-, Post-op, 1 year), 
Pain relief Brace and Analgesic use (Pre- and follow up) 
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Table 2: Patients demographics (pt # 21 to 40), VAS (Pre-, Post-op, 1 year), 
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Vertebral Height A-P Left



























































Table 3: Left Vertebral height measurements 
in MPR Mid-Coronal reconstruction. Pre-op, post-op, 1-y 
    
 
Vertebral Height A-P Center



























Table 4: Center Vertebral height measurements 
in MPR Mid-Coronal reconstruction. Pre-op, post-op, 1-y 
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Vertebral Height A-P Right



















Table 5: Right Vertebral height measurements 






Vertebral Height L-L Anterior


















Table 6: Anterior Vertebral height measurements 
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Vertebral Height L-L Center

























Table 7: Center Vertebral height measurements 
in MPR Mid-Sagittal reconstruction. Pre-op, post-op, 1-y 
 
Vertebral Height L-L Posterior
































Table 8: Posterior Vertebral height measurements 
in MPR Mid-Sagittal reconstruction. Pre-op, post-op, 
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Fig. 1: a) vertebral fracture in the lateral view b) and in the antero-posterior 
view c) CT-like axial MPR reconstruction performed to check needle 
correct pathway d) manual drilling performed to create the channels 
forthe implant in the closed fashion e) Rotational flat-panel 
angiographic equipment with cone beam-CT capabilities (Philips 




Antonio MANCA - Vertebral Augmentation with Nitinol Endoprosthesis: Clinical Experience  with one year 
follow-up in 40 patients 
Tesi Dottorato in Scienze Biomediche – Università degli Studi di Sassari 
61 
 








Fig. 2: a) Vertelift implants in the open fashion in lateral view b) and in the 
antero-posterior view (XX fashion) c) VerteLift implant in the opened 
fashion once detached from delivery system in lateralview d) and A-P 
view e) manual opening and positioning of VerteLift using handles 
(“amber” prototype) under fluoroscopic guidance  f) VerteLift 
implant in the closed fashion g) and in the open fashion (asymmetric) 
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Fig. 3: a) Vertelift implants encased in bone cement in lateral view b) and in 
the antero-posterior view  c) Height measurement before implant expansion in 
mid-sagittal MPR reconstruction d) Height measurements (3 point) before 
implant expansion in mid-coronal MPR reconstruction e) Height measurement 
after implant expansion and PMMA injection in mid-sagittal f) Height 
measurement after implant expansion and PMMA injection in mid-coronal 
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Fig. 4) First row from left to right: Magnetic Resonance of the spine 
T1, T2, STIR sequences showing a wedge fracture with bone marrow edema 
before vertebral augmentation  
Second row from left to right: Magnetic Resonance of the spine performed at 1-
year (pt #23) T1, T2, STIR sequences showing no more edema after vertebral 
aumentation, no new fractures and no significant artifact (just a mild signal 
void) of VerteLift implant 
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